Neurosense Therapeutics Stock Price Patterns
| NRSN Stock | USD 0.92 0.03 3.16% |
Momentum 50
Impartial
Oversold | Overbought |
EPS Estimate Current Year (0.40) | EPS Estimate Next Year (0.18) | Wall Street Target Price 11.5 |
Using Neurosense Therapeutics hype-based prediction, you can estimate the value of Neurosense Therapeutics from the perspective of Neurosense Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Neurosense Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Neurosense because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Neurosense Therapeutics after-hype prediction price | USD 0.92 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Neurosense | Build AI portfolio with Neurosense Stock |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Neurosense Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neurosense Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Neurosense Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Neurosense Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Neurosense Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neurosense Therapeutics' historical news coverage. Neurosense Therapeutics' after-hype downside and upside margins for the prediction period are 0.05 and 7.09, respectively. We have considered Neurosense Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Neurosense Therapeutics is abnormally volatile at this time. Analysis and calculation of next after-hype price of Neurosense Therapeutics is based on 3 months time horizon.
Neurosense Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Neurosense Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurosense Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neurosense Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.02 | 6.20 | 0.00 | 0.00 | 6 Events / Month | 5 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.92 | 0.92 | 0.00 |
|
Neurosense Therapeutics Hype Timeline
Neurosense Therapeutics is now traded for 0.92. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Neurosense is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is now at -0.02%. %. The volatility of related hype on Neurosense Therapeutics is about 2683.98%, with the expected price after the next announcement by competition of 0.92. About 26.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.36. Neurosense Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 6 days. Check out Neurosense Therapeutics Basic Forecasting Models to cross-verify your projections.Neurosense Therapeutics Related Hype Analysis
Having access to credible news sources related to Neurosense Therapeutics' direct competition is more important than ever and may enhance your ability to predict Neurosense Therapeutics' future price movements. Getting to know how Neurosense Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neurosense Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| NRXS | Neuraxis | (0.01) | 9 per month | 4.24 | 0.10 | 7.88 | (7.62) | 38.80 | |
| KLTO | Klotho Neurosciences | 0.00 | 6 per month | 0.00 | (0.16) | 10.34 | (8.57) | 28.13 | |
| CLGN | Collplant Biotechnologies | 0.16 | 6 per month | 0.00 | (0.04) | 8.51 | (7.84) | 25.76 | |
| XCUR | Exicure | (1.02) | 9 per month | 8.49 | 0.02 | 21.22 | (11.88) | 63.80 | |
| CVKD | Cadrenal Therapeutics Common | (0.96) | 8 per month | 0.00 | (0.10) | 8.11 | (8.29) | 58.15 | |
| ENLV | Enlivex Therapeutics | 0.03 | 3 per month | 4.25 | (0) | 8.57 | (8.16) | 24.21 | |
| SONN | Sonnet Biotherapeutics Holdings | (0.58) | 8 per month | 0.00 | (0.02) | 19.48 | (18.21) | 69.59 | |
| NERV | Minerva Neurosciences | 0.03 | 3 per month | 0.00 | (0.02) | 6.88 | (9.05) | 25.06 | |
| RLYB | Rallybio Corp | 0.01 | 6 per month | 3.04 | 0.02 | 8.33 | (5.71) | 21.25 | |
| TAOX | TAO Synergies | 0.03 | 9 per month | 0.00 | (0.11) | 12.66 | (10.43) | 36.28 |
Neurosense Therapeutics Additional Predictive Modules
Most predictive techniques to examine Neurosense price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neurosense using various technical indicators. When you analyze Neurosense charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Neurosense Therapeutics Predictive Indicators
The successful prediction of Neurosense Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Neurosense Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Neurosense Therapeutics based on analysis of Neurosense Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Neurosense Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neurosense Therapeutics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 0.84 | 2.21 | 2.54 | 2.41 | Net Debt To EBITDA | 0.26 | 0.33 | 0.38 | 0.37 |
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Neurosense Stock
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurosense Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could Neurosense diversify its offerings? Factors like these will boost the valuation of Neurosense Therapeutics. Anticipated expansion of Neurosense directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurosense Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Neurosense Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Neurosense Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Neurosense Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Neurosense Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurosense Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Neurosense Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.